(IL-118570) 1. Use of an effective amount, sufficient to at least reduce the growth of adenocarcinoma or hepatocarcinoma, of at least one fused chimeric protein comprising a linear genetically engineered molecule consisting essentially of peptide bonds, produced by fusing, at the level of cDNA: A. DNA encoding at least one cell targeting moiety consisting essentially of methionine gonadotropin releasing hormone (Met-GnRH) or a Met-GnRH analog that specifically binds to GnRH binding sites on Caco2 adenocarcinoma cells; and B. DNA encoding at least one cell killing moiety, in the preparation of a pharmaceutical composition for use in a method for the treatment of said adenocarcinoma or hepatocarcinoma in a mammal in need of such therapy. 2. A use according to claim 1, wherein said fused chimeric protein is produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a mutated DNA fragment of the full length Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE66. 3. A use according to claim 1, wherein said fused chimeric protein produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a DNA fragment comprising domains II and III of the Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE40. 4. A use in according to claim 1, wherein said pharmaceutical composition for systemic administration of said chimeric protein. 5. A use of a fused chimeric protein comprising a linear genetically engineered molecule consisting essentially of peptide bonds, produced by fusing, at the level of cDNA: A. DNA encoding at least one cell targeting moiety consisting essentially of Met- GnRH or a Met-GnRH analog that specifically binds to GnRH binding sites on Caco2 adenocarcinoma cells; and B. DNA encoding at least one cell killing moiety in the preparation of a pharmaceutical composition for use in a method of treating a mammal having at least one adenocarcinoma or hepatocarcinoma, comprising administering to said mammal in need thereof, an amount sufficient to ameliorate the effects of said adenocarcinoma or hepatocarcinoma. 6. A use of a fused chimeric protein comprising a linear genetically engineered molecule consisting essentially of peptide bonds, produced by fusing, at the level of cDNA: A. DNA encoding at least one cell targeting moiety consisting essentially of Met- GnRH or a Met-GnRH analog that specifically binds to GnRH binding sites on Caco2 adenocarcinoma cells; and B. DNA encoding at least one cell killing moiety in the preparation of a pharmaceutical composition for use in treating a mammal having endometriosis. 7. A use of a fused chimeric protein comprising a linear genetically engineered molecule consisting essentially of peptide bonds, produced by fusing, at the level of cDNA: A. DNA encoding at least one cell targeting moiety consisting essentially of Met- GnRH or a Met-GnRH analog that specifically binds to GnRH binding sites on Caco2 adenocarcinoma cells; and B. DNA encoding at least one cell killing moiety in the preparation of a pharmaceutical composition for use in treating a mammal having a uterine myoma. 8. A use of a fused chimeric protein comprising a linear genetically engineered molecule consisting essentially of peptide bonds, produced by fusing, at the level of cDNA: A. DNA encoding at least one cell targeting moiety consisting essentially of Met- GnRH or a Met-GnRH analog that specifically binds to GnRH binding sites on Caco2 adenocarcinoma cells; and B. DNA encoding at least one cell killing moiety in the preparation of a pharmaceutical composition for use in treating a mammal having a pituitary adenoma. 9. A use of a fused chimeric protein comprising a linear genetically engineered molecule consisting essentially of peptide bonds, produced by fusing, at the level of cDNA: A. DNA encoding at least one cell targeting moiety consisting essentially of Met - GnRH or a Met-GnRH analog that specifically binds to GnRH binding sites on Caco2 adenocarcinoma cells; and B. DNA encoding at least one cell killing moiety in the preparation of a pharmaceutical composition for use in treating a mammal having benign prostatic hyperplasia (BPH). 10. A use of a fused chimeric protein comprising a linear genetically engineered molecule consisting essentially of peptide bonds, produced by fusing, at the level of cDNA: A. DNA encoding at least one cell targeting moiety consisting essentially of Met- GnRH or a Met-GnRH analog that specifically binds to GnRH binding sites on Caco2 adenocarcinoma cells; and B. DNA encoding at least one cell killing moiety in the preparation of a pharmaceutical composition for use in treating a mammal having polycystic breast disease. 11. A use according to claim 5, wherein said fused chimeric protein is produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a mutated DNA fragment of the full length Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE66. 12. A use according to claim 5, wherein said fused chimeric protein is produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a DNA fragment comprising domains II and III of the Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE40. 13. A use according to claim 6, wherein said fused chimeric protein is produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a mutated DNA fragment of the full length Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE66. 14. A use according to claim 6, wherein said fused chimeric protein is produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a DNA fragment comprising domains II and III of the Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE40. 15. A use according to claim 7, wherein said fused chimeric protein is produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a mutated DNA fragment of the full length Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE66. 16. A use according to claim 7, wherein said fused chimeric protein is produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a DNA fragment comprising domains II and III of the Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE40. 17. A use according to claim 8, wherein said fused chimeric protein is produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a mutated DNA fragment of the full length Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE66. 18. A use according to claim 8, wherein said fused chimeric protein is produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a DNA fragment comprising domains II and III of the Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE40. 19. A use according to claim 9, wherein said fused chimeric protein is produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a mutated DNA fragment of the full length Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE66. 20. A use according to claim 9, wherein said fused chimeric protein is produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a DNA fragment comprising domains II and III of the Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE40. 21. A use according to claim 10, wherein said fused chimeric protein is produced by fusing at the CDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a mutated DNA fragment of the full length Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE66. 22. A use according to claim 10, wherein said fused chimeric protein is produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GNRH analog, preceded by a Met, to a DNA fragment comprising domains II and III of the Pseudomonas exotoxins (PE), encoding the protein Met-GnRH-PE40. 23. For the Applicants, RE HOLD COH ND PARTNERS By
最新评论
暂无评论。